Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Gross Margin (2016 - 2025)

Historic Gross Margin for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to 58.33%.

  • Guided Therapeutics' Gross Margin changed N/A to 58.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.92%, marking a year-over-year increase of 102900.0%. This contributed to the annual value of 28.57% for FY2024, which is 81600.0% down from last year.
  • Latest data reveals that Guided Therapeutics reported Gross Margin of 58.33% as of Q3 2025.
  • Guided Therapeutics' 5-year Gross Margin high stood at 100.0% for Q2 2021, and its period low was 200.0% during Q4 2024.
  • Over the past 5 years, Guided Therapeutics' median Gross Margin value was 66.67% (recorded in 2024), while the average stood at 33.38%.
  • Per our database at Business Quant, Guided Therapeutics' Gross Margin crashed by -2716700bps in 2021 and then surged by 2210500bps in 2022.
  • Guided Therapeutics' Gross Margin (Quarter) stood at 68.33% in 2021, then soared by 46bps to 100.0% in 2022, then tumbled by -50bps to 50.0% in 2023, then crashed by -500bps to 200.0% in 2024, then soared by 129bps to 58.33% in 2025.
  • Its Gross Margin was 58.33% in Q3 2025, compared to 67.52% in Q2 2025 and 200.0% in Q4 2024.